America faces an affordability crisis like the one from 25 years ago, but needs a fresh solution

The article argues that U.S. affordability pressure is intensifying ahead of upcoming midterm elections as families face years of price hikes after the pandemic. It criticizes common cost-cutting approaches—"Costcofication," "Walmartfication," and "Taxpayerfication"—as either constrained, quality-damaging, or reliant on subsidies/taxes that only shift costs. It instead promotes an "innovate for emerging markets" playbook, citing examples like GE Healthcare’s Brivo CT at ~$56,000 manufacturing cost delivering 75% of Revolution scanner procedures (from ~$650,000), plus Gillette’s lower-part razor design and Innova Schools’ $130/month target with expansion to 63 schools serving 64,000 students by 2025.

Analysis

This is less a “prices go down” story than a design-intensity regime shift: the market will reward firms that can re-architect products around cost-per-outcome, not just those with the lowest sticker price. That favors GEHC-style software-plus-modularity models, where incremental demand can scale with limited bill-of-materials inflation and better service attach, while punishing businesses whose moat is mainly distribution or brand if they cannot defend value.

For COST and WMT, the near-term risk is not an earnings miss so much as multiple ceiling. If investors start to view affordability as already embedded in their proposition, the incremental upside from traffic share gains gets smaller, while any slip in basket economics or membership conversion looks more sensitive. Over 1-3 months, election rhetoric could temporarily support these names, but over 6-18 months the bigger issue is whether they can keep comping without leaning on mix or shrink-wrapped “good enough” product quality.

LEVI is the cleanest second-order loser: value-engineered substitutes and private-label imitation are exactly the mechanism that compresses pricing power in branded apparel. The contrarian point is that the consensus may be underestimating how bullish this is for industrial/healthcare innovators: affordability pressure creates a premium for firms that can deliver better performance at lower cost, which is a margin-expansion setup, not just a growth story. Falsifiers: GEHC failing to show order/margin conversion from emerging-market style products, or COST/WMT continuing to take share without margin degradation through the next two quarters.

Key Decisions for Investors

• Long GEHC on a 1-3 month horizon; thesis is mix shift toward lower-cost, software-enabled systems with higher incremental margin. Add on pullbacks unless order growth or gross margin trajectory stalls.
• Relative-value pair: long GEHC / short WMT or COST basket for 3-6 months, sized modestly. This expresses 'engineering leverage' vs 'retail affordability saturation'; stop out if WMT/COST continue to expand membership/traffic without margin erosion.
• Underweight or tactical short LEVI vs apparel/consumer basket into the next earnings cycle. Risk/reward improves if wholesale sell-through weakens or gross margin guidance reflects heavier discounting.
• If already long COST or WMT as defensive quality, trim 10-20% into strength and rotate part of the capital toward GEHC and other value-engineering beneficiaries. The article argues the easy affordability trade is mature.
• Watchlist, not a trade: if GEHC does not translate product redesign into visible emerging-market revenue growth within 1-2 quarters, the narrative is just commentary. Reassess on the next guide.